Status:
COMPLETED
Study In Patients With Dyslipidaemia
Lead Sponsor:
GlaxoSmithKline
Conditions:
Metabolic Syndrome X
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Study in patients with dyslipidaemia.
Eligibility Criteria
Inclusion
- Waist circumference =102cm (men) or =88cm (women) at visit 1.
- Fasting plasma HDL C =40mg/dL (1.03mmol/L) (men) or =50mg/dL (1.29mmol/L) (women) at Screening Visit 1.
- Fasting TGs =150mg/dL (1.69mmol/L) and =800mg/dL (8.96mmol/L) at Screening Visit 1.
- Subjects whose plasma LDL C concentration does not require treatment according to the NCEP ATP III guidelines at Screening Visit 1.
Exclusion
- History of diabetes
- History of cardiovascular disease
- Diagnosis of genetic lipid disorders
- History of muscle pain
- History of cancer
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT00264667
Start Date
December 1 2005
End Date
June 1 2007
Last Update
October 28 2016
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, 1425
2
GSK Investigational Site
Córdoba, Córdoba Province, Argentina, 5000
3
GSK Investigational Site
Buenos Aires, Argentina
4
GSK Investigational Site
Córdoba, Argentina, 5016